Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ACTR3 antisense RNA 1 (ACTR3-AS1), also known as AC104653.1, is a long non-coding RNA (lncRNA) gene classified as an antisense RNA transcript[3]. Antisense lncRNAs like ACTR3-AS1 are transcribed from the DNA strand opposite a protein-coding gene—in this case, ACTR3—and often regulate the expression of their sense partner gene through various mechanisms such as recruiting chromatin modifiers, modulating transcript stability, or influencing methylation patterns[1][2]. These molecules can impact gene expression post-transcriptionally in the cytoplasm or influence epigenetic states within the nucleus[1][2]. While the general class of antisense lncRNAs is recognized for diverse roles in cancer progression and gene regulation, there is limited direct evidence specifically linking ACTR3-AS1 to a well-defined therapeutic mechanism, disease biomarker status, or drug interactions[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ACTR3 antisense RNA 1 (ACTR3-AS1).